Sana Biotechnology, Inc. (SANA) News
Follow Sana Biotechnology, Inc. (SANA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Sana Biotechnology 3Q 2026: EPS $0.07 — 10-Q Summary
Sana Biotechnology reported a quarterly profit after a year-earlier loss, as a $63.4 million gain from changes in the fair value of success payment and contingent consideration liabilities—primarily reflecting an August
EARNINGS | Nov 05, 2026, 09:25 PM UTC
L
Form SCHEDULE 13G/A Sana Biotechnology, Inc. Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:25 PM UTC
L
SANA: IND and phase I/II trial for diabetes therapy and first-in-human CAR T data expected within 12 months
Two innovative platforms are advancing: a hypoimmune cell therapy for type 1 diabetes, with an IND and phase I/II trial planned by year-end, and an in vivo CAR T platform targeting cancer, with first-in-human data for SG
NEWS | Sep 15, 2026, 04:33 PM UTC
L
SANA: Clinical milestones for diabetes and CAR T therapies are on track, with key trials imminent
Significant progress was highlighted for both the type 1 diabetes and in vivo CAR T platforms, with key clinical milestones expected in the next 12 months. Strategic collaboration with Mayo Clinic is accelerating trial r
NEWS | Sep 15, 2026, 04:07 PM UTC
L
SANA: Gene-edited islet therapy for type 1 diabetes nears clinical trial, with CAR T data expected in 2027
The discussion highlighted progress toward a gene-edited, stem cell-derived islet therapy for type 1 diabetes, with IND clearance and a phase I trial expected this year. The in vivo CAR T platform is advancing, with clin
NEWS | Sep 14, 2026, 10:58 PM UTC
L
SANA: Gene-modified islet cell therapy for type 1 diabetes nears phase I trial, with strong clinical and financial momentum
The company is advancing gene-modified islet cell therapy for type 1 diabetes, aiming to start a phase I trial by year-end, and is developing an in vivo CAR T platform for blood cancers. Manufacturing scalability, regula
NEWS | Sep 14, 2026, 09:52 PM UTC
L
Sana signals progress on gene-modified islet and in vivo CAR T programs
TradingView News says Sana is progressing toward a one-time gene-modified islet therapy for type 1 diabetes, with IND filing and phase I/II trials expected soon. In vivo CAR T programs are also advancing, focused on safe
EQUITY | Sep 08, 2026, 03:13 PM UTC
M
Sana programs near clinical milestones; SC451 IND and dosing expected
Sana said SC451 is targeting type 1 diabetes and an in vivo CAR T platform is focused on oncology. An IND filing and initial patient dosing for SC451 are expected this year, with pivotal data anticipated next year.
EQUITY | Sep 08, 2026, 02:33 PM UTC
M
SANA platforms advance toward clinical trials for diabetes and cancer
Hypoimmune islet cell technology is advancing as a potential functional cure for type 1 diabetes, citing long-term cell survival and immune evasion without immunosuppression. Its in vivo fusosome CAR T platform is moving
EQUITY | Sep 08, 2026, 12:47 PM UTC
L
Sana Biotechnology updates corporate presentation on SC451 and CAR T programs
Sana Biotechnology said its updated corporate presentation outlines progress toward filing an IND for SC451 this year and advances in its in vivo CAR T fusosome programs.
REGULATION | Sep 08, 2026, 12:03 PM UTC
L
Sana Biotechnology to Present at September 2026 Investor Conferences
Sana Biotechnology announced it will present at September 2026 investor conferences.
EQUITY | Sep 01, 2026, 08:05 PM UTC
H
Sana Biotechnology Insiders Face Fiduciary Probe
Sana Biotechnology insiders probed for fiduciary breaches
EQUITY | Jul 29, 2026, 02:09 PM UTC
L
Sana Biotechnology To Present Data From Allogeneic Primary Islet Cell Therapy At European Association For The Study Of Diabetes
Sana Biotechnology, Inc. (NASDAQ: SANA ), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsor
EQUITY | Jul 01, 2026, 01:05 PM UTC